Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting
AMSTERDAM, The Netherlands, March 30, 2012 /PRNewswire/ –
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene
therapy, announced that the Extraordinary General Meeting (EGM) of shareholders was held
in Amsterdam, the Netherlands, today in accordance with the EGM Notice of February 17,
2012. At the EGM, shareholders approved all the resolutions proposed for the substantial
corporate restructuring and financing transaction, which will result in the assets and
certain liabilities being acquired by a newly formed private company, uniQure BV, and the
AMT legal entity being liquidated.
The shareholders in uniQure previously included a condition to the transaction that
meant an additional EUR 1.0 million of investment was to be secured by AMT prior to
completion. This condition has been waived. Completion of the uniQure transaction is
expected to occur in early April 2012. Further details on timing on the uniQure
transaction are set out on the company’s website.
The resolutions put to the EGM convened in accordance with the Notice were passed by a
majority in excess of 99 percent. The detailed voting information and results pursuant to
Section 2:120 paragraph 5 of the Dutch Civil Code will be posted on the website
http://www.amtbiopharma.com.
About Amsterdam Molecular Therapeutics
AMT is a world leader in the development of human gene based therapies. AMT has a
product pipeline of gene therapy products in development for hemophilia B, acute
intermittent porphyria, Parkinson’s disease and SanfilippoB. Using adeno-associated viral
(AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate probably the world’s first stable and scalable AAV
manufacturing platform. This proprietary platform can be applied to a large number of rare
(orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of
focusing on this sector of the industry. The assets of AMT are subject to a proposed
acquisition by uniQure BV. AMT was founded in 1998 and is based in Amsterdam. Further
information can be found at http://www.amtbiopharma.com.
About uniQure
uniQure BV is a private company created specifically to acquire specific assets and
liabilities of Amsterdam Molecular Therapeutics (AMT). The company is funded by Forbion
Capital Partners, an existing investor in AMT. uniQure will act as the new holding company
for the gene therapy business currently carried out by AMT.
Certain statements in this press release are “forward-looking statements” including
those that refer to management’s plans and expectations for future operations, prospects
and financial condition. Words such as “strategy,” “expects,” “plans,” “anticipates,”
“believes,” “will,” “continues,” “estimates,” “intends,” “projects,” “goals,” “targets”
and other words of similar meaning are intended to identify such forward-looking
statements. Such statements are based on the current expectations of the management of AMT
only. Undue reliance should not be placed on these statements because, by their nature,
they are subject to known and unknown risks and can be affected by factors that are beyond
the control of AMT. Actual results could differ materially from current expectations due
to a number of factors and uncertainties affecting AMT’s business. AMT expressly disclaims
any intent or obligation to update any forward-looking statements herein except as
required by law.
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
